FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2523361569> ?p ?o ?g. }

• W2523361569 abstract "Abstract Abstract 1010 Poster Board I-32 Invasive aspergillosis remains an important cause of death for AML patients. Recently a lot of efficient innovative agents have been proposed as curative, empiric and more recently prophylaxis therapy in the IFI setting. It has been demonstrated that some agents used either as early treatment or prophylaxis of IFI had a significant impact on early survival (Day 100) of AML patients. The principal aim of our study was to see if this observation was true when considering a long-term period and how the development of an IA during the AML story interferes on the therapeutic strategy and finally on the long-term survival. We decided to conduct a study in our centre from 2004 to 2009 on a cohort of AML patients and to compare patients who developed an IA with patients who never developed in IA during the period of observation. Chi2 test and Fischer exact test were used for the comparison of discrete variables, U Mann-Withney test for continuous variables, survival analysis used Kaplan-Meyer and Cox proportional hazard model. We studied a total of 267 patients which represented 151 716 patient-days at risk (415 patient-years) and the longer follow-up was 5.1 years. Sixty-three patients developed an IA: 7 (11%) proven, 24 (38%) probable and 32 (51%) possible. The median delay between chemotherapy induction and IA was 22 days (IQR 16-29). The characteristics of the population were 123 females and 144 males (54%) with a median age of 56.7 years (47.9-64.9). The performance status (PS) 0 (n=94/35%), 1 (n=102/38%), 2 (n=50/19%), 3 (n=13/5%), 4 (n=8/3%), FAB classification 0 (n=17/6%), 1 (n=45/17%), 2 (n=42/16%), 3 (n=20/8%), 4 (n=28/10%), 5 (n=68/26%), 6 (n=8/3%), 7 (n=14/5%) (25 patients were not classified) and the cytogenetics were favourable (n=26/10%), intermediate (n=98/38%) and unfavourable (n=111/42%) (26 patients were not classified). As induction treatment patients received standard chemotherapy (n=180/67%), intensive regimen (n=86/32%) and 1 patient (1%) received low dose chemotherapy. At the last follow-up 115 patients have relapsed (43%), 100 are alive and 167 died. All characteristics below were compared between patients with and without IA during their disease course and 4 variables were significantly different (Table 1).The probability of overall survival was at the end of induction (D 30): 95% (86-98) with IA and 98% (95-99) without IA, at day 100: 79% (67-87) with IA and 92% (88-96) without IA, at 1 year 49% (36-60) with IA and 66% (60-73) without IA, at 2 years 33% (21-46) with IA and 43% (37-51) without IA and at 4 years 15% (5-30) with IA and 32% (24-40) without IA(Figure 1). The median survival time was 1.51 years (95%CI 1.19-1.88) with 1 year (95%CI 0.60-1.89) with IA and 1.62 years (95%CI 1.33-2.18) without IA. The univariate analysis on OS showed a significant influence of IA (p=0.028), age (p<0.001), cytogenetics (p<0.001), chemotherapy (better survival for intensive therapy compared to standard p<0.001) and a trend for period of diagnosis (better survival in ≥2007 vs before 2007: p=0.08). The multivariate analysis showed a significant impact on OS of IA, age, PS and cytogenetics (Table 2).In conclusion, IA appears as a significant risk factor besides age, PS, cytogenetics either on short or on long-term survival in AML. Differences of IA incidence observed over time may be related to prophylaxis strategy (environment, antifungal prophylaxis) applied during different periods. These results point out the importance of antifungal prophylaxis for fit AML patients Disclosures: No relevant conflicts of interest to declare." @default.
• W2523361569 created "2016-09-30" @default.
• W2523361569 creator A5005285747 @default.
• W2523361569 creator A5009141408 @default.
• W2523361569 creator A5009327777 @default.
• W2523361569 creator A5013488023 @default.
• W2523361569 creator A5026989659 @default.
• W2523361569 creator A5032848974 @default.
• W2523361569 creator A5045261121 @default.
• W2523361569 creator A5045974510 @default.
• W2523361569 creator A5052966035 @default.
• W2523361569 creator A5057122590 @default.
• W2523361569 creator A5058778299 @default.
• W2523361569 creator A5062694494 @default.
• W2523361569 creator A5063798888 @default.
• W2523361569 creator A5071094899 @default.
• W2523361569 creator A5072027146 @default.
• W2523361569 creator A5072721892 @default.
• W2523361569 creator A5075488760 @default.
• W2523361569 creator A5077014294 @default.
• W2523361569 creator A5080330335 @default.
• W2523361569 creator A5086924438 @default.
• W2523361569 creator A5087988208 @default.
• W2523361569 date "2009-11-20" @default.
• W2523361569 modified "2023-09-30" @default.
• W2523361569 title "Invasive Aspergillosis: A New Important Risk Factor On Short and Long-Term Survival of AML Patients." @default.
• W2523361569 doi "https://doi.org/10.1182/blood.v114.22.1010.1010" @default.
• W2523361569 hasPublicationYear "2009" @default.
• W2523361569 type Work @default.
• W2523361569 sameAs 2523361569 @default.
• W2523361569 citedByCount "0" @default.
• W2523361569 crossrefType "journal-article" @default.
• W2523361569 hasAuthorship W2523361569A5005285747 @default.
• W2523361569 hasAuthorship W2523361569A5009141408 @default.
• W2523361569 hasAuthorship W2523361569A5009327777 @default.
• W2523361569 hasAuthorship W2523361569A5013488023 @default.
• W2523361569 hasAuthorship W2523361569A5026989659 @default.
• W2523361569 hasAuthorship W2523361569A5032848974 @default.
• W2523361569 hasAuthorship W2523361569A5045261121 @default.
• W2523361569 hasAuthorship W2523361569A5045974510 @default.
• W2523361569 hasAuthorship W2523361569A5052966035 @default.
• W2523361569 hasAuthorship W2523361569A5057122590 @default.
• W2523361569 hasAuthorship W2523361569A5058778299 @default.
• W2523361569 hasAuthorship W2523361569A5062694494 @default.
• W2523361569 hasAuthorship W2523361569A5063798888 @default.
• W2523361569 hasAuthorship W2523361569A5071094899 @default.
• W2523361569 hasAuthorship W2523361569A5072027146 @default.
• W2523361569 hasAuthorship W2523361569A5072721892 @default.
• W2523361569 hasAuthorship W2523361569A5075488760 @default.
• W2523361569 hasAuthorship W2523361569A5077014294 @default.
• W2523361569 hasAuthorship W2523361569A5080330335 @default.
• W2523361569 hasAuthorship W2523361569A5086924438 @default.
• W2523361569 hasAuthorship W2523361569A5087988208 @default.
• W2523361569 hasConcept C10515644 @default.
• W2523361569 hasConcept C126322002 @default.
• W2523361569 hasConcept C141071460 @default.
• W2523361569 hasConcept C203014093 @default.
• W2523361569 hasConcept C207103383 @default.
• W2523361569 hasConcept C2776391196 @default.
• W2523361569 hasConcept C2776611710 @default.
• W2523361569 hasConcept C2776694085 @default.
• W2523361569 hasConcept C2908647359 @default.
• W2523361569 hasConcept C44249647 @default.
• W2523361569 hasConcept C50382708 @default.
• W2523361569 hasConcept C71924100 @default.
• W2523361569 hasConcept C72563966 @default.
• W2523361569 hasConcept C99454951 @default.
• W2523361569 hasConceptScore W2523361569C10515644 @default.
• W2523361569 hasConceptScore W2523361569C126322002 @default.
• W2523361569 hasConceptScore W2523361569C141071460 @default.
• W2523361569 hasConceptScore W2523361569C203014093 @default.
• W2523361569 hasConceptScore W2523361569C207103383 @default.
• W2523361569 hasConceptScore W2523361569C2776391196 @default.
• W2523361569 hasConceptScore W2523361569C2776611710 @default.
• W2523361569 hasConceptScore W2523361569C2776694085 @default.
• W2523361569 hasConceptScore W2523361569C2908647359 @default.
• W2523361569 hasConceptScore W2523361569C44249647 @default.
• W2523361569 hasConceptScore W2523361569C50382708 @default.
• W2523361569 hasConceptScore W2523361569C71924100 @default.
• W2523361569 hasConceptScore W2523361569C72563966 @default.
• W2523361569 hasConceptScore W2523361569C99454951 @default.
• W2523361569 hasLocation W25233615691 @default.
• W2523361569 hasOpenAccess W2523361569 @default.
• W2523361569 hasPrimaryLocation W25233615691 @default.
• W2523361569 hasRelatedWork W1969575680 @default.
• W2523361569 hasRelatedWork W205570635 @default.
• W2523361569 hasRelatedWork W2241382955 @default.
• W2523361569 hasRelatedWork W2324845435 @default.
• W2523361569 hasRelatedWork W2522091244 @default.
• W2523361569 hasRelatedWork W2523628007 @default.
• W2523361569 hasRelatedWork W2529976270 @default.
• W2523361569 hasRelatedWork W2530502502 @default.
• W2523361569 hasRelatedWork W2530645474 @default.
• W2523361569 hasRelatedWork W2545597103 @default.
• W2523361569 hasRelatedWork W2551332475 @default.
• W2523361569 hasRelatedWork W2557651358 @default.
• W2523361569 hasRelatedWork W2560424423 @default.
• W2523361569 hasRelatedWork W2583894790 @default.
• W2523361569 hasRelatedWork W2979796411 @default.
• W2523361569 hasRelatedWork W2980287403 @default.

• next